SINGAPORE (Aug 27): As cancer rates rise, particularly in Asia, the fight to contain it becomes all the more urgent, yet treatment drugs are not always available, not for lack of advances in scientific research, either. “High-potential oncology drugs get neglected for reasons [that have] nothing to do with science but more to do with corporate limitations of the healthcare industry,” says Vishal Doshi, CEO of biomedical start-up AUM Biosciences in an interview with The Edge Singapore. AUM Biosciences is looking to change that. “We feel that it is the need of the hour,” says Doshi.

He points out that across the world, the cost of treating cancer is a lot higher than it is for any other disease. “It is actually impacting the availability and affordability of the drugs,” says Doshi, who started his career at US drug development services company PharmaNet Development Group.

AUM Biosciences is less than a year old, and has recorded barely any revenue, much less earnings. Yet, Doshi has raised $2 million in seed funding from investors happy to make an early bet.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook